The increased expression of MUC1 in the patients who succumbed to the COVID-19 infection further necessitates the expansion of clinical trials that involve the use of MUC1 inhibitors to treat patients with COVID-19 [9]. The gene discussed is MUC1; the disease is COVID-19.